Sun Pharmaceutical Industries said its Board of Directors approved issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis in one or more tranches for up to Rs 10,000 crore, with required disclosures to follow on issuance or allotment.

Sun Pharmaceutical Industries Limited agreed to buy US-based Organon for a record $11.75 billion earlier this year, and executive chairman Dilip Shanghvi said the deal will help the company launch innovative products globally by providing registration reach and infrastructure in Europe, China, Korea, Taiwan, Australia, Turkey, Brazil, Mexico and other markets and a higher share of innovative drugs.

Sun Pharmaceutical Industries Limited gained 0.77% to Rs 1,773.40 after Nomura retained its Buy rating following strong Indian Pharmaceutical Market growth in September. Nomura said Sun Pharma sales rose 21.5% year-on-year in September and 17.9% year-on-year for the quarter ended 2QFY27, among the leaders in the top 20 companies.

Sun Pharmaceutical Industries Limited is preparing to set up a greenfield project in Pithampur, Madhya Pradesh, with an investment of around Rs3,000 crore, expected to generate more than 1,750 jobs including 1,250 direct and 500 indirect jobs.

Sun Pharmaceutical Industries shares fell 0.26% to Rs 1,776.30 after the Supreme Court directed the Centre to constitute a committee to examine measures to prevent pharma companies from offering expensive gifts and incentives to doctors.